CY1111819T1 - Αντισωμα εναντι epcam και χρησεις αυτου - Google Patents

Αντισωμα εναντι epcam και χρησεις αυτου

Info

Publication number
CY1111819T1
CY1111819T1 CY20111100854T CY111100854T CY1111819T1 CY 1111819 T1 CY1111819 T1 CY 1111819T1 CY 20111100854 T CY20111100854 T CY 20111100854T CY 111100854 T CY111100854 T CY 111100854T CY 1111819 T1 CY1111819 T1 CY 1111819T1
Authority
CY
Cyprus
Prior art keywords
epcam antibody
mouse
entitled
therapeutic
high affinity
Prior art date
Application number
CY20111100854T
Other languages
Greek (el)
English (en)
Inventor
Anna Maria Anastasi
Fiorella Petronzelli
Santis Rita De
Saverio Alberti
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of CY1111819T1 publication Critical patent/CY1111819T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20111100854T 2007-04-04 2011-09-06 Αντισωμα εναντι epcam και χρησεις αυτου CY1111819T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07105628 2007-04-04
EP08759374A EP2142570B1 (en) 2007-04-04 2008-04-02 Anti-epcam antibody and uses thereof

Publications (1)

Publication Number Publication Date
CY1111819T1 true CY1111819T1 (el) 2015-10-07

Family

ID=38458122

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100854T CY1111819T1 (el) 2007-04-04 2011-09-06 Αντισωμα εναντι epcam και χρησεις αυτου

Country Status (21)

Country Link
US (1) US8318911B2 (enExample)
EP (1) EP2142570B1 (enExample)
JP (1) JP5631733B2 (enExample)
KR (1) KR101683884B1 (enExample)
CN (1) CN101970497B (enExample)
AT (1) ATE512988T1 (enExample)
AU (1) AU2008235566B2 (enExample)
BR (1) BRPI0810096A8 (enExample)
CA (1) CA2682296C (enExample)
CY (1) CY1111819T1 (enExample)
DK (1) DK2142570T3 (enExample)
EA (1) EA023679B1 (enExample)
ES (1) ES2367675T3 (enExample)
HR (1) HRP20110620T1 (enExample)
IL (1) IL201196A0 (enExample)
MX (1) MX2009010444A (enExample)
PL (1) PL2142570T3 (enExample)
PT (1) PT2142570E (enExample)
RS (1) RS52040B (enExample)
SI (1) SI2142570T1 (enExample)
WO (1) WO2008122551A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5686493B2 (ja) 2003-01-24 2015-03-18 ユニバーシティ・オブ・ユタＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｕｔａｈ テロメアの長さを決定することによって死亡の危険性を予測する方法
CN102439171B (zh) 2008-12-22 2017-07-14 犹他大学研究基金会 单色多重定量pcr
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
CN107315086B (zh) * 2011-06-29 2019-09-10 中央研究院 使用表面涂层对生物物质的捕获、纯化和释放
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
US9494500B2 (en) 2012-10-29 2016-11-15 Academia Sinica Collection and concentration system for biologic substance of interest and use thereof
HK1220737A1 (zh) 2013-05-22 2017-05-12 Telomere Diagnostics, Inc. 短端粒丰度的量度
WO2015153816A2 (en) 2014-04-01 2015-10-08 Academia Sinica Methods and systems for cancer diagnosis and prognosis
EP2998026B1 (en) 2014-08-26 2024-01-17 Academia Sinica Collector architecture layout design
CA2971169A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
WO2017023704A1 (en) * 2015-07-31 2017-02-09 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
AU2017301826A1 (en) 2016-07-26 2019-03-14 Tessa Therapeutics Ltd. Chimeric antigen receptor
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN119896730A (zh) 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
TW202039582A (zh) * 2019-04-22 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ＥｐＣＡＭ抗體及其應用
US11851499B2 (en) 2019-06-11 2023-12-26 Bioatla, Inc. Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN112094350B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体
JP7570653B2 (ja) * 2020-08-19 2024-10-22 ▲蘇▼州易慕峰生物科技有限公司 ヒト化抗体、キメラ抗原受容体、核酸、ベクター、細胞及び応用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
JP3427871B2 (ja) * 1996-06-24 2003-07-22 戸田工業株式会社 コバルト被着型針状磁性酸化鉄粒子粉末
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b

Also Published As

Publication number Publication date
PT2142570E (pt) 2011-09-13
CA2682296C (en) 2017-02-28
DK2142570T3 (da) 2011-10-03
AU2008235566A1 (en) 2008-10-16
EA023679B1 (ru) 2016-06-30
BRPI0810096A2 (pt) 2014-10-21
BRPI0810096A8 (pt) 2017-12-26
CN101970497B (zh) 2017-05-10
SI2142570T1 (sl) 2012-01-31
WO2008122551A9 (en) 2009-02-05
KR101683884B1 (ko) 2016-12-07
EP2142570B1 (en) 2011-06-15
HRP20110620T1 (hr) 2011-09-30
RS52040B (sr) 2012-04-30
IL201196A0 (en) 2010-05-17
US20100092491A1 (en) 2010-04-15
KR20100016237A (ko) 2010-02-12
WO2008122551A3 (en) 2008-12-04
PL2142570T3 (pl) 2011-11-30
EP2142570A2 (en) 2010-01-13
EA200970923A1 (ru) 2010-04-30
ATE512988T1 (de) 2011-07-15
WO2008122551A2 (en) 2008-10-16
AU2008235566B2 (en) 2013-06-06
JP2010523096A (ja) 2010-07-15
US8318911B2 (en) 2012-11-27
CA2682296A1 (en) 2008-10-16
JP5631733B2 (ja) 2014-11-26
CN101970497A (zh) 2011-02-09
MX2009010444A (es) 2009-10-20
ES2367675T3 (es) 2011-11-07

Similar Documents

Publication Publication Date Title
CY1111819T1 (el) Αντισωμα εναντι epcam και χρησεις αυτου
CY1123005T1 (el) Κατασκευασματα αντισωματος για cdh19 και cd3
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
CY1122669T1 (el) Σκευασματα αντισωματων αντισκληροστινης υψηλης συγκεντρωσης
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
GT201200271A (es) Proteínas que se unen al tnf-a
MX386942B (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
BR112012007523A2 (pt) moléculas de anticorpo anti-gcc e composições e métodos relacionados
CY1113087T1 (el) Ανθρωπινα αντισωματα εναντιον δελτα-παρομοιου προσδεματος 4
CY1115147T1 (el) Εξουδετερωτικα αντισωματα που εχουν ειδικοτητα για ανθρωπινη il-17
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
CY1113074T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
BR112013027829A2 (pt) anticorpos anti-cd40 e método de uso
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
MX2020009468A (es) Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20.
CL2019002716A1 (es) Métodos y composiciones para la reducción de inmunogenicidad
BR112022011032A2 (pt) Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
CL2011000911A1 (es) Composicion que comprende uno o mas antigenos, un solo dominio variable de inmunoglobulina antiproteina dc-sign y un vehiculo; metodo de elaboracion; y uso para el tratamiento de un tumor.
TR201902670T4 (tr) Anti-5t4 antikorları ve bunların kullanımları.